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Abstract
Introduction: Sepsis involves overwhelming inflammatory responses with subsequent immune-suppression that
can lead to multiple organ dysfunction and ultimately death. Milk fat globule epidermal growth factor-factor 8
(MFG-E8) is a secretory protein found to have multiple biological activities against autoimmune and inflammatory
diseases. MFG-E8 contains an Arg-Gly-Asp (RGD) motif involved in cell-cell and cell-matrix interactions. In sepsis,
excessive neutrophils migration through endothelial cells and matrix to sites of inflammation results in organ
damage. We hypothesized that MFG-E8-derived short peptides (MSP) flanking its RGD motif could provide
protection against organ injury in sepsis.
Methods: The differentiated human neutrophil-like HL-60 cells (dHL60) were incubated with a series of peptides
flanking the RGD motif of human MFG-E8 for a cell adhesion assay to fibronectin or human pulmonary artery
endothelial cells (PAECs). For the induction of sepsis, male C57BL/6 mice (20–25 g) were subjected to cecal ligation
and puncture (CLP). Peptide MSP68 (1 mg/kg body weight) or normal saline (vehicle) was injected intravenously at
2 h after CLP. Blood and tissue samples were collected at 20 h after CLP for various measurements.
Results: After screening, peptide MSP68 (VRGDV) had the highest inhibition of dHL-60 cell adhesion to fibronectin
by 55.8 % and to PAEC by 67.7 %. MSP68 treatment significantly decreased plasma levels of organ injury marker
AST by 37.1 % and the proinflammatory cytokines IL-6 and TNF-α by 61.9 % and 22.1 %, respectively after CLP.
MSP68 improved the integrity of microscopic architectures, decreased IL-6 levels in the lungs by 85.1 %, and
reduced apoptosis. MSP68 treatment also significantly reduced the total number of neutrophil infiltration by 61.9 %
and 48.3 % as well as MPO activity by 40.8 % and 47.3 % in the lungs and liver, respectively, after CLP. Moreover,
the number of bacteria translocated to mesenteric lymph nodes was decreased by 57 % with MSP68 treatment.
Finally, the 10-day survival rate was increased from 26 % in the vehicle group to 58 % in the MSP68-treated group.
Conclusions: MSP68 effectively inhibits excessive neutrophils infiltrating to organs, leading to moderate attenuation
of organ injury and significantly improved survival in septic mice. Thus, MSP68 may be a potential therapeutic
agent for treating sepsis.
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Introduction
Sepsis is defined as an infection-associated initial hyperinflammatory and subsequent immune-suppressive response, which leads to multiple organ dysfunction, shock,
secondary infections and lethality [1–3]. It is one of the
most prevalent diseases and accounts for 20 % of all
admission to intensive care units [4]. More than 800,000
people develop sepsis and septic shock annually, with an
overall mortality of 30 % in the USA [5, 6]. Despite the tremendous efforts in advancing the understanding of sepsis
progression and more than thirty failed clinical trials, there
is still no effective drug available to treat this disease
[7–10]. Undoubtedly, there is an urgent need to identify
and develop a new class of therapeutic agents against
sepsis and septic shock.
During the early stage of sepsis, neutrophils are recruited to the inflamed organs to contain and eradicate
invading pathogens [11]. These activated neutrophils release proteolytic enzymes and reactive oxygen species.
Although these released molecules help kill invading pathogens in sepsis, their excessive production disrupts the
endothelial barrier and causes extravascular tissue damage, contributing significantly to multiple organ failure
(MOF) and lethality [12–15]. Examination of autopsy
specimens from patients with MOF reveals large-scale
neutrophil infiltration of the lungs [16]. Thus, a therapeutic strategy designed to attenuate neutrophil infiltration has the potential to prevent organ injury and reduce
mortality in sepsis [17, 18].
Human milk fat globule epidermal growth factorfactor 8 (MFG-E8) is a secretory 387-amino acid (aa)
protein composed of a N-terminal cleavable signal peptide, one epidermal growth factor (EGF)-like domain,
and two C-terminal discoidin domains which resemble
the sequences of blood coagulation factors V and VIII
[19]. The EGF-like domain contains an arginine-glycineaspartate (RGD) motif which binds integrins of macrophages, while the discoidin domains bind phosphatidylserine, thus opsonizing apoptotic cells and promoting their
engulfment by macrophages [19, 20]. Therefore, MFG-E8
facilitates the clearance of apoptotic cells by phagocytosis
and reduces inflammatory responses, resulting in protection of animals from intestinal injury and sepsis [21, 22].
In addition, MFG-E8 directly inhibits proinflammatory
cytokine release from immune cells via attenuation of the
NF-κB pathway [23]. We have also identified that MFGE8 is a novel regulator of neutrophil infiltration in acute
lung injury [24, 25].
Neutrophil recruitment is a multiple-step process
[26–28]. Under the normal condition, neutrophils roll
along microvascular walls via low affinity interaction
of selectins with endothelial cells. During inflammation,
chemotactic factors induced by proinflammatory cytokines signal the recruitment of neutrophils into the sites
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of infection and/or injury. This leads to the activation of
neutrophil integrins and the subsequent high-affinity
binding of neutrophils to the activated endothelial cells in
postcapillary venules. Under the influence of chemotactic
gradients, neutrophils penetrate the endothelial layer and
migrate through connective tissue to the sites of infection,
where they finally congregate and adhere to extracellular
matrix (ECM) components [29]. The binding of integrins
on neutrophils to their ligands, especially containing the
RGD sequence, is very crucial for this recruiting process
[30]. Thus, we further examined whether the RGD motif
in MFG-E8 was responsible for its activity in regulating
neutrophil infiltration.
In the present study, we first screened a number of
peptides derived from the sequence flanking RGD domain of human MFG-E8 by assessing their inhibition of
neutrophil adhesion to fibronectin and endothelial cells.
We then examined the effect of treatment with the identified peptide on the neutrophil trafficking and organ injury
in septic mice induced by cecal ligation and puncture
(CLP), a physiologically relevant model. This approach
would not only dissect the specific domain of MFG-E8 in
regulating neutrophil infiltration but also evaluate the
potential of using MFG-E8-derived smaller peptides as a
therapeutic strategy for treating sepsis.

Methods
Cell lines

Human promyelocytic leukemia cell line HL-60 and primary pulmonary artery endothelial cells (PAECs) were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). HL-60 cells were cultured
in RPMI medium (Invitrogen, Carlsbad, CA, USA) containing 10 % fetal bovine serum (FBS), 2 mM L-glutamine and 1 % penicillin and streptomycin. HL-60 cells
were differentiated into neutrophil-like cells (dHL-60) by
adding dimethyl sulfoxide at 12.7 μl/ml/million cells for
5 days. PAECs were cultured in vascular cell basal medium
supplemented with endothelial cell growth kit-VEGF
(ATCC).
Cell adhesion assay

The dHL-60 cells were labeled with calcein AM (Life
Technologies, Grand Island, NY, USA). 1.5 × 105 labeled
dHL-60 cells were added to 96-well plates coated with
10 μg/ml fibronectin (Life Technologies) or 10,000
PAECs/well in the presence of phosphate-buffered saline
(PBS) or various concentrations (0.5 and 5 μg/ml) of
synthesized small peptides derived from human MFG-E8
(GenScript, Piscataway, NJ, USA). The plates were incubated at 37 °C in 5 % CO2 for 2 h. Non-adherent
cells were washed away with PBS and attached cells
were detected using a fluorescence plate reader at
485 nm/530 nm.
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Mice

Male C57BL/6 mice (20 to 25 g) purchased from Taconic
Biosciences (Albany, NY, USA) were used in all experiments at 8–12 weeks of age. These mice were housed in a
temperature-controlled room on a 12-h light/dark cycle in
the animal facility within the Feinstein Institute for
Medical Research (Manhasset, NY, USA) and fed a
standard laboratory diet. All experiments were performed in accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health (Bethesda, MD, USA)
and were approved by the Institutional Animal Care and
Use Committee (IACUC) at the Feinstein Institute for
Medical Research. All efforts were made to minimize
suffering.
Cecal ligation and puncture (CLP)

Sepsis was induced in mice using the CLP procedure.
The mice were anesthetized by isoflurane inhalation, and
the abdomen was shaved and cleaned with 10 % povidone iodine. A 1-cm to 2-cm midline incision was performed to expose the cecum, which was tightly ligated
with a 4-0 silk suture at 1 cm from the tip. The ligated
cecum was double punctured with a 22-gauge needle,
gently squeezed to expel a small amount of feces from
the perforation sites and returned to the peritoneal cavity. The laparotomy site was then closed with a 6-0 silk
suture in two layers. The sham animals underwent the
same procedure but the cecum was neither ligated nor
punctured. The operated animals were resuscitated and
1 ml of normal saline was given by subcutaneous injection immediately after the surgery to improve dehydration. At 20 h after CLP or sham operation, mice were
anesthetized and blood, liver, and lungs were collected.
Blood samples were centrifuged at 3,000 g for 10 minutes
to collect plasma. A section of lung tissue was preserved
in formalin for histopathological analysis. The plasma
and remainder of tissue samples were frozen immediately in liquid nitrogen, and stored at −80 °C until analysis. An additional set of experiments were performed
for harvesting the livers, lungs and peritoneal fluids for
leukocyte preparation 20 h post-CLP or sham. For the
survival study, mice were subcutaneously administered
0.5 mg/kg of antibiotic PRIMAXIN (Merck, Whitehouse
Station, NJ, USA) after CLP and were monitored for ten
days to record survival.
Administration of MSP68

Mice were allocated to three groups: sham, vehicle, or
treatment. Two hours after CLP, a small incision on the
neck was made and the internal jugular vein was exposed. Normal saline (vehicle) or MSP68 (GenScript) at
a dose of 1 mg/kg body weight (BW) in 200 μl volume
was delivered by injection using a 29G × 1/2″ U-100
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insulin syringe (Terumo Medical Corporation, Elkton,
MD, USA) through the jugular vein.
Measurements of cytokine and organ injury marker

Interleukin (IL)-6 and tumor necrosis factor (TNF)-α
levels in the plasma samples and lung tissues were quantified using mouse enzyme-linked immunosorbent assay
(ELISA) kits (BD Biosciences, Franklin Lakes, NJ, USA).
Plasma levels of aspartate aminotransferase (AST) were
measured using a commercial assay kit (Pointe Scientific,
Lincoln Park, MI, USA) according to the manufacturer’s
instructions.
Histologic examination

The lung tissues were fixed in 10 % formalin followed by
paraffin embedding. The paraffin tissue blocks were cut
into 5-μm sections, which were transferred to glass
slides and stained with hematoxylin and eosin (H&E).
Morphologic changes in the lung tissues were examined
by light microscopy, documented by photographs and
evaluated by two investigators in a blinded manner.
Lung injury was assessed according to the following
pathological features: (1) alveolar wall thickening, (2) vascular congestion, (3) intra-alveolar hemorrhage, (4) interstitial leukocyte infiltration, and (5) alveolar leukocyte
infiltration. A semiquantitative scoring system based on
the presence and severity of each of these features was
used to designate scores from 0 to 3 for absent, mild,
moderate, or severe injury and a cumulative total histology
score was determined.
TUNEL assay

A TUNEL (terminal deoxynucleotidyl transferase dUTP
nick end-labeling) staining kit (Roche Diagnostics,
Mannheim, Germany) was used to detect the presence
of apoptotic cells in the lung sections according to the
manufacturer’s instructions. The negative control was
performed by incubating slides in the mixture containing
only deoxynucleotidyl transferase. TUNEL-positive cells
were counted in 10 microscopic fields per section under
a fluorescence microscope (×200).
Western blotting

Lung tissues were homogenized in lysis buffer (10 mM
Tris-HCl, pH 7.5, 120 mM NaCl, 1 % NP-40, 1 % sodium deoxycholate, and 0.1 % SDS) containing a protease inhibitor cocktail (Roche Diagnostics) by sonication.
Protein concentrations were determined by Bio-Rad
Laboratories (Hercules, CA, USA) protein assay reagent.
Lysates from lungs were fractionated on Bis-Tris gels
(4–12 %) and transferred to nitrocellulose membrane.
The membranes were then blocked with 5 % nonfat dry
milk in Tris-buffered saline with Tween-20 and incubated
with anti-cleaved caspase-3 (Cell Signaling Technology,
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Beverly, MA, USA) or anti-β-actin (Sigma-Aldrich, St
Louis, MO, USA) antibodies. The bands were visualized
using Pierce ECL 2 Western Blotting Substrate (Thermo
Scientific, Southfield, MI, USA).
Leukocyte suspension preparation from lungs and livers

Complete RPMI medium was prepared with 10 % FBS,
1 % Penn-Strep, 10 mM HEPES (4-(2-hydroxyethyl)-1piperazineethanesulfonic acid), 2 mM L-Glutamine, and
5 × 10−5 M β-mercaptoethanol. Lungs were minced and
digested in complete RPMI medium containing 100 U/ml
collagenase type 1 (Worthington Biochemical, NJ, USA)
and 20 U/ml DNase 1 (Roche Diagnostics) for 30 minutes
at 37 °C in a shaker incubator. Lung leukocytes were
isolated by density-gradient centrifugation (2,000 rpm,
20 minutes) using 44 % and 66 % Percoll (GE Healthcare
Bio-Sciences AB, Uppsala, Sweden). Cells at the interface
and below were collected, washed with PBS and resuspended in complete RPMI. Livers were minced and
homogenized in PBS with 1 % FBS, followed by Percollgradient centrifugation similar to lungs for isolation of
hepatic leukocytes. The total leukocytes numbers isolated
from lungs and livers were determined by counting aliquots in a hemocytometer using the trypan blue exclusion
method.
Neutrophil staining and flow cytometry

Cells (1 × 106) obtained from livers and lungs were preincubated with anti-mouse CD16/CD32 (93) to block
FcγRII/III receptors. These cells were then stained for
30 minutes on ice with allophycocyanin (APC) conjugated
anti-mouse Ly-6G (1A8) and peridinin chlorophyll proteincyanine 5.5 (PerCP/Cy5.5) conjugated anti-mouse CD11b
(M1/70) antibodies (Biolegend, San Diego, CA, USA) for
staining neutrophils. The stained samples were acquired
using the FACSVerse (BD Bioscience, San Jose, CA, USA).
Forward light scatter or forward light scatter plus propidium iodide was used to exclude dead cells. The data were
analyzed by FlowJo software (Tree Star, Ashland, OR,
USA). The neutrophil numbers in livers and lungs were
determined using the following formula:
Neutrophil numbers ¼ Total leukocytes recovered
 Neutrophil percentage=100:
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Oxidative burst measurement of peritoneal neutrophils

Spontaneous neutrophil oxidative burst activity was
measured by flow cytometry by quantifying the conversion of dihydrorhodamine 123 (DHR) to rhodamine 123
as previously described [31]. Peritoneal cells were harvested from mice under isoflurane anesthesia. After
aseptic preparation of the abdominal wall, 5 ml of sterile
cold PBS with 1 % FBS was injected and aspirated into
the peritoneal cavity twice. Cells in peritoneal washes were
washed with PBS and counted. Peritoneal lavage cells were
incubated with 50 μM of DHR (Life Technologies) at 37 °C
for 30 minutes. DHR-stained cells were pre-incubated with
anti-mouse CD16/CD32 (93) for 10 minutes followed by
15 minutes incubation with APC-anti-mouse Ly-6G (1A8)
and PerCP/Cy5.5-anti-mouse CD11b (M1/70) antibodies
(Biolegend) on ice. A minimum of 10,000 events were collected and analyzed using the FACSVerse.
Bacterial counts

Bacterial counts were performed on mesenteric lymph
nodes (MLN) which were aseptically harvested from
mice under isoflurane anesthesia. Equal amounts of wet
MLN were homogenized in sterile PBS at 4 °C and samples were serially diluted in sterile PBS. Log dilutions
were plated on trypticase soy agar plates with 5 % sheep
blood (BD Diagnostic Systems, Sparks, MD, USA),
which were incubated at 37 °C for 24 h under aerobic
conditions. The colony-forming units (CFU) were
counted and the results were expressed as colony forming units (CFU) per mg of tissue (MLN).
Statistical analysis

Data were analyzed using SigmaPlot11 graphing and
statistical analysis software (Systat Software Inc., San
Jose, CA, USA) and expressed as mean ± standard error of
the mean (SEM). One-way analysis of variance (ANOVA)
was used for comparing multiple groups with StudentNewman-Keuls’ (SNK) test. Student’s t test was used for
two-group analysis. The Kaplan-Meier method was used
for analyzing the survival data and comparisons between
groups were done using the log-rank test. Differences in
values were considered significant if P was <0.05.

Results
MSP68 inhibits neutrophil adhesion

Myeloperoxidase (MPO) activity assay

Lung tissues were homogenized in potassium phosphate
buffer containing 0.5 % hexa-decyl-trimethyl-ammonium
bromide by sonication. After centrifugation the supernatant
was diluted in reaction solution containing o-dianisidine
hydrochloride and hydrogen peroxide. The rate of change
in optical density per minute was measured at 460 nm to
calculate MPO activity.

Cell adhesion plays an important role in the migration of
neutrophils through the endothelium and extracellular
matrix to sites of injury and inflammation and involves
integrin binding. We synthesized a series of peptides (up
to 15-mer) flanking the RGD sequence of human MFGE8 (Fig. 1a) and extensively screened them by an in vitro
cell adhesion assay to test their effect on neutrophil adhesion. Among them, a 5-aa peptide with the sequence
valine-arginine-glycine-aspartate-valine (VRGDV), named
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Fig. 1 MFG-E8-derived short peptide 68 (MSP68) inhibits adhesion of neutrophils. a Schematic diagram showing a series of synthesized peptides
flanking the arginine-glycine-aspartate (RGD) sequence of human MFG-E8 including the 5-aa peptide MSP68 with the valine-arginine-glycine-aspartate-valine (VRGDV) sequence. Calcein AM-labeled differentiated HL-60 cells were added to microtiter plates coated with fibronectin (FN)
(10 μg/ml) (b) or 10,000 pulmonary artery endothelial cells (PAECs)/well (c) in the presence of vehicle (phosphate buffered saline (PBS)) or an indicated
concentration of MSP68 and incubated at 37 °C for 2 h. Adhered dHL60 cells were detected using a fluorescence plate reader at 485 nm/530 nm. The
fluorescence values for cells adhered to FN or PAEC in the presence of PBS are designated as 100 % adhesion. Data are expressed as mean ±
standard error of the mean obtained from two independent experiments (n = 3/group) and compared by Student’s t test; *P <0.05 versus PBS

MSP68, showed the most inhibition of the neutrophil
adhesion to both fibronectin and endothelial cells. As seen
in Fig. 1b, calcein AM-labeled dHL60 cells attached to
fibronectin in the presence of PBS as 100 % adhesion,
while MSP68 peptide significantly reduced the fibronectin
adhesion of dHL60 cells by 44.3 % at 0.5 μg/ml and by
55.8 % at 5 μg/ml (Fig. 1b). Similarly, adhesion of dHL60
neutrophils to PAECs was reduced by 14.7 % and 67.7 %
in the presence of 0.5 and 5 μg/ml of MSP68, respectively,
compared to PBS (Fig. 1c).

MSP68 treatment reduces organ injury and systemic
inflammation in sepsis

Sepsis is known to induce injury in multiple distant
organs. Accordingly, the plasma levels of multiple organ
injury marker, AST, were significantly increased by 10.8fold in the vehicle group at 20 h after CLP, compared to
the sham group (Fig. 2a). However, with MSP68 treatment, AST levels in these septic mice were 37.1 % lower
than those in the vehicle-treated mice (Fig. 2a). The
increase of plasma IL-6 levels has been correlated with

Fig. 2 MFG-E8-derived short peptide 68 (MSP68) reduces organ injury after cecal ligation and puncture (CLP). Male C57BL/6 mice were shamoperated or subjected to CLP with injection of vehicle (normal saline) or MSP68 (1 mg/kg body weight) at 2 h after CLP. Blood samples were
collected at 20 h after CLP to measure aspartate aminotransferase (AST) using the commercial assay kit (a), interleukin-6 (IL-6) (b) and tumor
necrosis factor-α (TNF-α) (c) using enzyme-linked immunosorbent assay. Data are expressed as means ± standard error of the mean (n = 6 mice/group)
and compared by one-way analysis of variance and Student–Newman–Keuls method; *P <0.05 versus sham and #P <0.05 versus vehicle
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the severity of sepsis [32, 33]. Indeed, IL-6 plasma levels
were significantly increased by 10.7-fold in the vehicle
group at 20 h after CLP, compared to the sham group
(Fig. 2b). However, the IL-6 levels in the MSP68 group
were 61.9 % lower than those in the vehicle group (Fig. 2b).
Plasma levels of another proinflammatory cytokine,
TNF-α, were also 5.9-fold higher in the vehicle group
than the sham group and were decreased by 22.1 %
on MSP68 treatment (Fig. 2c).
MSP68 treatment attenuates sepsis-induced lung injury

Acute lung injury is one of the most frequent complications of sepsis [34], so we examined the histological
architecture of lungs at 20 h after CLP. The H&E staining
revealed substantial morphological changes, including hemorrhage, edema, alveolar collapse, and infiltration of
inflammatory leukocytes in the lung tissues of the vehicletreated mice, compared to the sham mice (Fig. 3a). In
contrast, the lung tissues from the MSP68-treated
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mice exhibited improved lung morphology with reduced
microscopic deterioration, compared to the vehicle group
(Fig. 3a). As quantified in Fig. 3b, the histological lung
damage score in the vehicle group increased 3.6-fold in
comparison with the sham group, while this score was significantly reduced by 56.5 % in the MSP68-treated mice.
In addition, MSP68 treatment also significantly decreased
the lung IL-6 protein level by 85.1 % in comparison with
the vehicle group (Fig. 3c).
Next, we performed a TUNEL assay on the lung
tissues to investigate the effect of MSP68 treatment on
lung apoptosis. The number of TUNEL-positive cells in
the lung tissues of the vehicle group was markedly increased after CLP in comparison with the sham groups
in which they were barely detectable (Fig. 4a). However,
the number of apoptotic cells in the lung tissues of the
MSP68-treated mice was significantly reduced by 64.4 %
in comparison with the vehicle group (Fig. 4b). Similarly,
the expression of cleaved caspase-3 in the lung tissues

Fig. 3 MFG-E8-derived short peptide 68 (MSP68) attenuates lung damage after cecal ligation and puncture (CLP). Male C57BL/6 mice were
sham-operated or subjected to CLP with injection of vehicle (normal saline) or MSP68 (1 mg/kg body weight) at 2 h after CLP. The lung tissues
were harvested at 20 h after CLP. a Sections of lung tissues were stained with hematoxylin and eosin, and examined under light microscopy.
Representative images at original magnification × 200 are shown. b Histological lung injury scores from the above mentioned mice groups,
determined as described in “Methods”, are shown. c Protein was extracted from the lung tissues to measure interleukin-6 (IL-6) levels by enzymelinked immunosorbent assay. Data are expressed as means ± standard error of the mean (n = 4–6/group) and compared by one-way analysis of
variance and Student–Newman–Keuls test; *P <0.05 versus sham and #P <0.05 versus vehicle
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Fig. 4 MFG-E8-derived short peptide 68 (MSP68) reduces apoptosis in the lungs after cecal ligation and puncture (CLP). Male C57BL/6 mice were
sham-operated or subjected to CLP with injection of vehicle (normal saline) or MSP68 (1 mg/kg body weight) at 2 h after CLP. The lung tissues
were harvested at 20 h after CLP. a Sections of lung tissues were stained with terminal deoxynucleotidyl transferase dUTP nick end-labeling
(TUNEL) (green fluorescent), nuclear counterstained (red fluorescent), and examined under fluorescent microscopy. Representative images at original
magnification × 200 are shown. b The numbers of apoptotic cells quantified from the TUNEL staining (averaged over 10 microscopic fields per
mouse) are shown. c Protein was extracted from the lung tissues for western blotting. Representative blots for cleaved caspase-3 and loading
β-actin control, and graph for their densitometric analysis are presented. Data are expressed as means ± standard error of the mean (n = 4–6/group)
and compared by one-way analysis of variance and Student–Newman–Keuls test; *P <0.05 versus sham and #P <0.05 versus vehicle

of the MSP68-treated mice was reduced by 17.7 % in
comparison with that in the vehicle group (Fig. 4c).
Taken together, our data suggest that MSP68 treatment
improved CLP-induced lung damage and attenuated
apoptotic cell death in the lungs.
MSP68 treatment reduces neutrophil infiltration in the
lungs and liver in sepsis

Neutrophil sequestration and activation in the lungs and
liver are critical for causing acute injury in sepsis [14, 35].
To evaluate the neutrophil infiltration in the lungs and
liver, we isolated leukocytes from these tissues and stained
with Ly6G and CD11b surface markers to identify neutrophils. In the lungs, frequency of Ly6G+CD11b+ neutrophils in the vehicle group was increased by 5.3-fold in
comparison with the sham group, while it was reduced by

37.0 % in the MSP68 group (Fig. 5a, b). Accordingly, the
total number of lung neutrophils increased by 9.5-fold in
the vehicle group, but reduced by 61.9 % with MSP68
treatment (Fig. 5c). Myleoperoxidase (MPO) activity correlates well with tissue neutrophil content and is used as a
marker for neutrophil infiltration in the tissues. In consistence, there was a 5.9-fold increase of the lung MPO activity in the vehicle group in comparison with the sham
group (Fig. 5d). With MSP68 treatment, the lung MPO
activity was reduced by 40.8 % (Fig. 5d).
In the liver, the frequency of Ly6G+CD11b+ neutrophils was also significantly increased after CLP; however,
it was reduced by 32.5 % in the MSP68 group in comparison with the vehicle group (Fig. 6a, b). Similar to the
lungs, the total number of liver neutrophils increased
54.4-fold in the vehicle group, but reduced by 48.3 %
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Fig. 5 MFG-E8-derived short peptide 68 (MSP68) inhibits neutrophil infiltration in the lungs after cecal ligation and puncture (CLP). The lung
tissues from sham, vehicle and MSP68-treated mice were harvested at 20 h after CLP. a Single cell suspensions of leukocytes were stained with
allophycocyanin (APC)-anti-mouse Ly-6G and peridinin chlorophyll protein-cyanine (PerCP/Cy5.5)-anti-mouse CD11b, followed by flow cytometric
analysis. Representative dot plots of surface Ly6G/CD11b expression on gated live lung leukocytes. Numbers adjacent to outlined areas show the
percentage of Ly6G+CD11b+ neutrophils as indicated. The graphs show percentage (b) and total numbers of neutrophils in the lungs (c). d Lung
tissues were homogenized and myeloperoxidase (MPO) activity was determined spectrophotometrically. Data are expressed as mean ± standard
error of the mean (n = 4–6/group) and compared by one-way analysis of variance and Student–Newman–Keuls test; *P <0.05 versus sham and
#
P <0.05 versus vehicle

with MSP68 treatment (Fig. 6c). In addition, the liver
MPO activity in the vehicle group was increased 12.8fold in comparison with the sham group, while it was reduced by 47.3 % in the MSP68 group (Fig. 6d). These results collectively show that MSP68 treatment attenuates
CLP-induced lung and liver injury by reducing the associated neutrophil infiltration.
MSP68 treatment does not hinder oxidative function of
peritoneal neutrophils in sepsis

Neutrophils generate reactive oxygen species (ROS)
during phagocytosis, which can result in damage of host
tissues. On the other hand, this functional response,
termed oxidative burst, is also part of a powerful germkilling system of neutrophils [36]. As we noticed decreased neutrophil infiltration in the lungs and liver after
CLP, we examined whether MSP68 treatment affected
the oxidative function of neutrophils needed for eliminating bacteria. Representative histogram overlays showed
increased DHR fluorescence in peritoneal neutrophils
from the vehicle and MSP68 groups, compared to the
sham group (Fig. 7a). However, there was no difference
in their spontaneous oxidative burst activity between the
MSP68-treated and vehicle groups at 20 h after CLP

(Fig. 7b). These data showed that oxidative function of
peritoneal neutrophils remains intact after MSP68 treatment in septic mice.
MSP68 treatment prevents bacterial translocation in sepsis

Bacterial translocation is the migration of viable bacteria
from the gastrointestinal tract to normally sterile extraintestinal sites, such as the mesenteric lymph nodes
(MLN), which results in worsening of the outcome of
sepsis [37]. To investigate the effect of MSP68 treatment
on the extent of bacterial translocation in sepsis, we collected MLN from sham, vehicle and MSP68-treated mice
at 20 h after CLP. Sterile suspensions from homogenized
MLN were cultured for 24 h to assess the bacterial counts.
No bacteria were detected in the MLN cultures from the
sham group, whereas bacterial colonies were found in both
vehicle and MSPP68 groups. Colony counts were significantly reduced by 57 % in the MLN cultures from MSP68treated mice, compared to the vehicle group (Fig. 8).
MSP68 treatment improves the survival of septic mice
induced by CLP

To explore the long-term effect of MSP68 treatment on
the septic mice, we performed a 10-day survival study
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Fig. 6 MFG-E8-derived short peptide 68 (MSP68) inhibits neutrophil infiltration in the liver after cecal ligation and puncture (CLP). The liver
tissues from sham, vehicle and MSP68-treated mice were harvested at 20 h after CLP. a Single cell suspensions of leukocytes were stained with
allophycocyanin (APC)-anti-mouse Ly-6G and peridinin chlorophyll protein-cyanine 5.5 (PerCP/Cy5.5)-anti-mouse CD11b, followed by flow
cytometric analysis. Representative dot plots of surface Ly6G/CD11b expression on gated live liver leukocytes. Numbers adjacent to outlined areas
show the percentage of Ly6G+CD11b+ neutrophils as indicated. The graphs show percentage (b) and total numbers (c) of neutrophils in the liver.
d Liver tissues were homogenized and myeloperoxidase (MPO) activity was determined spectrophotometrically. Data are expressed as mean ± standard
error of the mean (n = 4–6/group) and compared by one-way analysis of variance and Student–Newman–Keuls test; *P <0.05 versus sham
and #P <0.05 versus vehicle

Fig. 7 MFG-E8-derived short peptide 68 (MSP68) does not affect oxidative burst activity of neutrophils after cecal ligation and puncture (CLP).
Peritoneal fluids from sham, vehicle and MSP68-treated mice were harvested at 20 h after CLP and processed to obtain single cell suspensions.
Isolated peritoneal cells were incubated with 50 μM of dihydrorhodamine 123 (DHR) at 37 °C for 30 minutes, followed by staining with allophycocyanin
(APC)-anti-mouse Ly-6G and peridinin chlorophyll protein-cyanine 5.5 (PerCP/Cy5.5)-anti-mouse CD11b. Flow cytometry was done to quantify the
fluorescence from DHR. a Representative histogram overlays show the flow cytometric analysis of DHR on the gated peritoneal neutrophils. b The
graphs show the spontaneous neutrophil oxidative burst activity as the mean fluorescence intensity (MFI) of DHR on gated peritoneal neutrophils. Data
are expressed as mean ± standard error of the mean (n = 3/group) and compared by one-way analysis of variance and Student–Newman–Keuls test;
*P <0.05 versus sham
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Fig. 8 MFG-E8-derived short peptide 6 (MSP68) prevents bacterial
translocation to mesenteric lymph nodes (MLN) after cecal ligation
and puncture (CLP). MLN were aseptically collected at 20 h after CLP
from sham, vehicle and MSP68-treated mice and homogenized in
sterile PBS. The serially diluted MLN suspensions were plated, and
bacterial colony forming units (cfu) were calculated. Data are expressed
as mean ± standard error of the mean (n = 4–6/group) and compared
by Student’s t test; #P <0.05 versus vehicle. ND not detectable

on mice injected with vehicle or 1 mg/kg BW of MSP68
at 2 h after CLP. As shown in Fig. 9, the survival rate
after CLP in vehicle-treated animals was 56.5 % on day
2, and gradually decreased to 26 % on days 6–10. Administration of MSP68 significantly improved the 10-day
survival rate increasing it to 54 % with improvement in
survival starting as early as day 2 (Fig. 9).

Fig. 9 MFG-E8-derived short peptide 6 (MSP68) improves the
survival in cecal ligation and puncture (CLP)-induced sepsis. Mice
were subjected to CLP followed by a single subcutaneous injection
of 0.5 mg/kg antibiotic. At 2 h after CLP, mice were injected with
normal saline as vehicle (n = 23) or 1 mg/kg of MSP68 (n = 24)
through the jugular vein and survival was recorded for 10 days. The
survival rate was estimated by the Kaplan–Meier method and
compared using the log-rank test; *P = 0.05 versus vehicle
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Discussion
Despite advances in the management of sepsis patients,
a large number of those patients die from the ensuing
septic shock and MOF. Thus, there is an urgent unmet
medical need for a novel and effective therapy for sepsis.
Excessive recruitment of activated neutrophils into various tissues is a major contributing factor for causing
organ injury in sepsis. Previous study from our lab has
demonstrated the beneficial effect of MFG-E8 in reducing
inflammatory responses and organ injury, and improving
survival in a CLP-induced sepsis model [22, 38–41]. Earlier, we have also discovered a novel property of MFG-E8
in inhibiting the infiltration of activated neutrophils
[24, 25], in addition to its activity on enhancing the clearance of apoptotic cells [42, 43]. However, the significance
of the contribution of the MFG-E8 RGD motif in interfering with neutrophil infiltration has not been addressed.
In this study, we screened numbers of human MFGE8-derived peptides flanking the RGD sequence, which
could be involved in its binding to integrins. We have
identified a short peptide, named MSP68, which strongly
inhibits neutrophil adhesion to fibronectin and endothelial
cells. We have demonstrated that post-treatment with
MSP68 significantly reduces the inflammatory response
by decreasing the IL-6 levels systemically and locally, and
attenuates organ damage in septic mice. We have also
shown that MSP68 treatment improves the integrity of
the lung tissue and decreases lung apoptosis. Furthermore,
MSP68 treatment effectively inhibits neutrophil infiltration to the organs, demonstrated by the reduction in the
number of Ly6G+CD11b+ neutrophils and MPO activity
in the lungs and liver of septic mice. However, MSP68
treatment does not hinder the oxidative function of peritoneal neutrophils in killing bacteria in septic mice. In
fact, it decreases the bacterial translocation in septic mice.
Finally, MSP68 treatment markedly increased 10-day survival of mice with CLP-induced sepsis.
Integrins are heterodimeric proteins composed of noncovalently associated α and β chains and are located on
the cell surface to mediate cell-cell and cell-matrix interactions [30]. Twenty-four different integrins have been
identified in humans [30]. Integrins αLβ2 and αMβ2 are
the most important for neutrophils to bind to intercellular
adhesion molecule 1 on endothelial cells. Integrin α4β1 is
also used by neutrophils for binding to endothelial vascular cell adhesion molecule. Other integrins α5β1, αIIbβ1,
and αVβ3, interact with several extracellular matrix components, such as fibronectin and collagen, by recognizing
the tripeptide sequence RGD [30]. Neutrophils also bind
to fibronectin and endothelial cells via integrins β2 which
can also recognize RGD [30]. The relative affinity and specificity of the RGD peptides to different adhesion receptors have been indicated to be influenced by their flanking
sequences and conformation [44]. The MSP68 (VRGDV)

Yang et al. Critical Care (2015) 19:375

peptide demonstrated here shows interference with a
broad spectrum of integrins to interact with various adhesion receptors, resulting in inhibition of neutrophil adhesion to fibronectin and endothelial cells. The specificity of
physical interaction between MSP68 and different adhesion receptors is under investigation in our laboratory.
Effectiveness of synthetic RGD peptides in attenuating
the lipopolysaccharide (LPS)-, mechanical ventilationand intestinal ischemia-reperfusion (I/R)- induced lung
injury has been demonstrated previously [45–47]. Their
protective effects are attributed to inhibition of the infiltration of neutrophils and macrophages in the lung tissue
and to the levels of TNF-α, IL-6, monocyte chemoattractant protein-2 and matrix metalloproteinase-9 [45–47].
Specifically, the synthetic RGD peptides inhibit integrin αvβ3-mediated signaling in LPS- and mechanical
ventilation-induced lung injury models [45, 46]. RGDcontaining peptides have also been shown to protect
the liver from cold I/R injury in steatotic liver transplants
by inhibiting the recruitment of macrophages and neutrophils via blockade of integrin α5β1-fibronectin interactions
and by reducing the expression of pro-inflammatory
mediators, such as inducible nitric oxide synthase and
interferon-gamma and matrix metalloproteinase-9 [48, 49].
Similar to our findings, a recent study has also reported a protective effect of synthetic RGD peptides in
sepsis-induced ALI [50]. That study shows that administration of RGD peptides reduces systemic as well as lung
levels of TNF-α and IL-6, and improves histopathology
of lung tissue; however, the involvement of neutrophils
has not been investigated [50]. By applying MSP68, we
have further demonstrated the RGD peptide effectively
decreases the total number of neutrophils infiltrating the
lungs and liver, which is associated with reducing the
severity of organ injury in septic mice. However, we have
only examined architectural changes in the lungs with
regard to organ injury in this study. Whether MSP68
treatment can also alleviate the sepsis-induced impairment of pulmonary and liver function needs further
investigation. Also, sepsis commonly causes acute kidney
injury which has not been the focus of this study. Further
studies are needed to determine the effect of MSP68 treatment on the sepsis-induced acute kidney injury. Correspondingly, we have previously shown that administration
of recombinant murine MFG-E8 can decrease neutrophil
migration in LPS-induced acute lung injury by disrupting
the interaction with integrin αvβ3 [24]. These studies further support the approach of targeting integrin-mediated
signaling using RGD-based peptides to control neutrophil
infiltration into the organs, which subsequently induce
organ injury in sepsis.
In addition to our data showing that MSP68 reduces
excessive organ infiltration of neutrophils by inhibiting
their adhesion, there are other mechanisms by which the
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decreased neutrophil content in the studied organs
could be explained. Interestingly, integrin-mediated adhesion of neutrophils with endothelial cells/matrix has
been reported to interfere with neutrophil life span,
delaying their spontaneous apoptosis [51]. As prolonged
neutrophil survival is part of the pathogenesis of sepsis,
there is a possibility that MSP68 could be reducing the
life span of neutrophils resulting into less accumulation
in the organs. Whether or not MSP68 alters the phagocytic function of neutrophils under normal as well as
septic conditions also remains to be investigated. A
future study is granted to delineate the different possible mechanisms by which MSP68 can exert its positive
effect on improving neutrophil-related organ injury in
sepsis.
Maintenance of normal intestinal epithelial structure
and function is important in preventing movement of
bacteria and increased intestinal permeability has been
reported in sepsis [52]. Bacterial translocation is associated with an increased risk of complications, MOF, or
even mortality in critically ill sepsis patients [37]. We
have previously shown that recombinant murine MFGE8 treatment reduces the bacterial translocation to the
MLN after gut I/R injury [53]. The current study shows
that a 5-aa short peptide derived from human MFGE-8
sequence flanked RGD motif is also capable of lowering
the bacterial translocation to MLN in a mouse model of
CLP-induced sepsis. However, we have only counted viable bacteria in the MLN and not measured products
from dead bacteria. Sepsis is known to impair the immune system, which is unable to effectively clear bacteria and bacterial products. Therefore, increase in levels
of translocated viable bacteria and bacterial products
could result from combined dysfunction of the intestinal
barrier and the immune system, and not necessarily
from increased intestinal permeability alone. Nevertheless, increased viable bacteria in MLN indicate increased
risk of progression of infection in sepsis. As MSP68 does
not affect the oxidative burst activity of peritoneal neutrophils, its reduction of bacterial translocation is most
likely an indirect effect. In agreement with our observation, another study showed that treatment with synthetic
RGD peptides modulated inflammation in sepsis but had
no effect on peritoneal fluid bacterial load [50].
The CLP mouse model used in this study showed
74 % mortality in the vehicle group by day 10 which
went down to 46 % after MSP68 treatment. However, we
do recognize the limitations associated with the use of
CLP models. CLP tends to have variable mortality rates
based on differences between the strains and age of the
animals, length of the ligated cecum, needle size and
number of punctures, fluid resuscitation, and antibiotic
treatment [8]. Also in this study, we administered
MSP68 at 1 mg/kg BW and showed its beneficial effects
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in sepsis. Recent reports have used synthetic RGD peptides at 5 mg/kg BW to show significant inhibition of
neutrophils infiltrating the lungs in the LPS-, intestinal
I/R- and CLP-induced ALI model [45, 47, 50]. We therefore speculate that administration of MSP68 at the
5 mg/kg dose may increase its protective effect in CLPinduced sepsis. On the other hand, much higher doses
may lessen its protective effect because neutrophils are
necessary for the killing of invading pathogens. In the
current study, we have administered normal saline as
vehicle to be used as a baseline for comparing the effect
of MSP68 administration on the outcome of sepsis. Scrambled peptide sequence used as control would have further
assured that the effects are MSP68-peptide-specific and
not potential unidentified off-target effects.

Conclusions
In conclusion, data provided in this study identifies an
MFG-E8 derived short-peptide, MSP68, which inhibits
neutrophil adhesion. Treatment with MSP68 moderately
attenuates sepsis-induced organ injury and systemic inflammation. In particular, MSP68 improves the histopathology of the lung tissue. MSP68 does so by effectively
inhibiting the sepsis-induced excessive neutrophil infiltration into the lungs and liver. MSP68 treatment also
reduces bacterial translocation and prolongs the survival
of mice after sepsis. Thus, MSP68 may be a potential therapeutic agent for treating sepsis.
Key messages
 A short peptide, named MSP68, derived from milk









fat globule epidermal growth factor-factor 8 (MFG-E8)
is identified as a novel inhibitor of neutrophil adhesion
Post-treatment with MSP68 in CLP-induced sepsis
there are reduced systemic levels of organ injury
marker and pro-inflammatory cytokines IL-6 and
TNF-α
MSP68 treatment improves CLP-induced
histopathology along with attenuating inflammation
and apoptotic cell death in the lungs, which is
associated with inhibition of the excessive neutrophil
infiltration in the organs of septic animals
MSP68 treatment does not hinder with the oxidative
function of peritoneal neutrophils but reduces
CLP-induced bacterial translocation
MSP68 treatment improves the survival of mice
with CLP-induced sepsis
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